Thursday, July 27, 2017 2:22:10 PM
The decision to include HER exon 20 was made by MD Anderson, not SPPI. I trust them. But i don't trust SPPI. And as a shareholder since 2005 one should have learned his lesson. But if someone independent says the drug has high promises then my ears are open. And i trust even Hamni more than Raj an Joe. Still miserable and greedy management, that hasn't changed.... but they probably sit on two good drugs. And at least one that could sell from alone (poziotinib)...
If they make decisions to include a wider set of patients it could be because of other reasons - f.e. to speed up the enrollement. Like they decided to cut the rolontis trial to 400 to keep the promise to deliver data in the first half of 2018 and because they where hinted by the FDA that they have to do a second trial - which they take a high risk with only shortly above 200 patients. They increase the risk in rolontis significantly and they abandon the chance to show superiority...
Recent SPPI News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 11/09/2023 10:00:17 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/28/2023 04:15:27 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 09/26/2023 09:23:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM